Personal Risk

Picture this: it’s open enrollment season. Your HR manager — who is also your office manager, your compliance point person, and the person who orders coffee – is fielding the same 47 employee questions she answered last year. Meanwhile, three employees chose the wrong plan because they didn’t understand how the deductible worked. Two more never enrolled at all.

This used to be the price of being a small or mid-size employer. You didn’t have a benefits technology budget. You worked with what the carrier gave you: a PDF, a 1-800 number, and a prayer.

That’s changing fast and in 2026, it’s changing in ways that actually matter for employers with 25 to 500 employees.

What AI Benefits Tools Actually Do

Let’s be specific, because “AI” gets attached to every product description regardless of what the technology actually does. In benefits administration, the tools earning the label fall into a few practical categories.

Decision support at enrollment

AI-driven recommendation engines analyze an employee’s life stage, dependent status, and historical plan utilization to guide them toward better plan choices during open enrollment. Platforms like Bswift’s Emma and Employee Navigator’s decision support tools now serve mid-market clients — not just enterprise — and have demonstrated meaningful improvements in plan selection accuracy. According to Clarity Benefit Solutions, AI enrollment guidance can increase HSA contribution rates by 15-25% through better education during the enrollment process alone.

Year-round benefits Q&A

Instead of employees calling HR to ask whether their dentist is in-network or whether they can add a dependent after a qualifying life event, AI chatbots handle these queries in real time, around the clock. The Hartford’s 2026 Future of Benefits Study found that 95% of employers said they want digital tools for routine, transactional tasks — freeing HR staff for the complex issues that actually need human judgment.

Compliance monitoring and eligibility validation. AI systems can flag eligibility anomalies, track ACA reporting deadlines, and monitor regulatory changes across jurisdictions before they become audit findings. For a small HR team without a dedicated compliance specialist, this is where the ROI is most immediate.

What’s Actually Affordable Now

The pricing shift is real. Platforms like Gusto, BambooHR, and Employee Navigator all offer AI-assisted benefits administration at per-employee-per-month pricing that puts the technology within reach of employers who couldn’t consider it two years ago. SHRM’s 2026 State of AI in HR report found that AI in HR is now present in 21% of organizations in the HR technology practice area — and growing. The same report found that 87% of CHROs expect greater AI adoption within HR processes in 2026, up from 83% in 2025.

The pattern from The Hartford’s research is telling: 54% of employers say HR technology and benefits platforms are “highly influential” in selecting benefits carriers and vendors. The technology has moved from back-office tool to strategic differentiator.

What to Ask Before You Buy

Not all AI benefits tools are created equal. Before evaluating any platform, get clear on three questions:

• Does it integrate with your payroll system? A benefits platform that doesn’t talk to your payroll creates more manual work than it saves. Ask for a specific list of HRIS and payroll integrations before any demo.
• Who owns the data, and how is it protected? Employee health and benefits data is sensitive. Understand where your data is stored, whether the vendor uses it for model training, and what happens to it when your contract ends.
• Where does the human support kick in? The best implementations combine digital self-service for routine tasks with experienced specialists for complex claims, disability leave, or sensitive situations. A chatbot that handles open enrollment questions well is a feature. A chatbot that handles a difficult disability claim poorly is a liability.

Your HR technology consulting and HCM consulting teams are the right starting point for navigating the vendor landscape — especially if you’re evaluating platforms alongside a benefits renewal. The technology decision and the benefits strategy decision don’t happen in isolation anymore.

An HR team of two can now administer benefits like a team of twenty. The tools are here. The question is whether you’re using them.

Ready to explore what AI-powered benefits administration looks like for your organization? The team at Tooher-Ferraris has been helping businesses work smarter since 1932. Contact us today to schedule a no-obligation consultation.

Here is the situation. Employers are projecting a 10% increase in health care costs in 2026, according to the International Foundation of Employee Benefit Plans — and GLP-1 weight-loss medications are sitting at the center of that number. These drugs now account for an estimated 14% of all prescription drug spending nationally. Your employees know what Ozempic and Wegovy are. Some of them are already asking whether their plan covers it. And if you haven’t built a deliberate GLP-1 employer coverage strategy, your next renewal is going to force the conversation whether you’re ready or not.

This isn’t just a large-company problem. Mid-size employers on self-funded or level-funded plans are navigating the same pressure — and in some ways face harder tradeoffs, with less negotiating leverage and tighter stop-loss arrangements.

What’s Actually at Stake

GLP-1 drugs run approximately $400 to $700 per member per month on employer health plans. That’s before rebates — and rebate structures vary significantly depending on your pharmacy benefit manager (PBM) contract. For a plan covering 200 employees, even modest GLP-1 utilization can shift your pharmacy line item materially within a single plan year.

One PBM-reported case cited by the Program on Health Technology and Innovation found that an employer’s pharmacy spend “shot through” projected budgets by mid-June after adding broad GLP-1 coverage for weight loss. That’s not an outlier. It’s increasingly the norm for plans that add coverage without building guardrails first.

At the same time, the clinical case for these medications is real. A 2024 analysis by Aon found that GLP-1 users showed a 3% increase in medical cost growth over 18 months — versus 9% for a control group. Long-term reductions in cardiovascular claims, hospitalizations, and bariatric surgery are plausible outcomes.

The Three Positions Employers Are Taking

Right now, employers are clustering into three broad coverage approaches, each with real tradeoffs:

1. Diabetes-only coverage. This approach covers GLP-1 medications for FDA-approved type 2 diabetes treatment only and excludes obesity indications. It controls incremental cost, but it’s becoming harder to defend as clinical evidence for cardiovascular benefit expands and employee expectations shift.
2. Managed access with guardrails. This is where most mid-size employers finding sustainable outcomes are landing. Prior authorization, clinical eligibility criteria above the FDA label, required participation in a lifestyle or weight management program, and quantity limits combine to create coverage that’s defensible, fair, and measurable. According to Mercer, about 38% of employers with GLP-1 coverage now require lifestyle program participation as a condition of continued access.
3. Full exclusion. This was a common default in 2023 and 2024. In 2026, it creates increasing competitive and equity pressure — particularly in labor markets where GLP-1 access has become a visible benefits differentiator.

What to Do Before Your Next Renewal

Start by auditing what your plan is actually paying today. Many employers discover GLP-1 utilization already in their claims data — often under diabetes indications — before a formal obesity coverage policy is in place. Understanding your baseline is the prerequisite to everything else.

Engage your PBM or broker on utilization management options: prior authorization, indication-specific coverage, step therapy, and preferred drug list positioning. Review your stop-loss contract language specifically — some carriers are adding GLP-1-specific exclusions or adjusting attachment points, which creates a gap in your catastrophic cost protection that requires a plan design response.

Finally, build your employee communication now. GLP-1 drugs are heavily marketed directly to consumers. Employees will ask questions. A clear FAQ that explains what your plan covers, what it doesn’t, and why — applied consistently across all eligible employees — reduces confusion, limits informal escalations to HR, and protects you from claims of disparate treatment.

Your benefits strategy team can help you model the budget impact of different coverage approaches before you commit. Your pharmacy management strategy is equally critical — PBM contract structure and formulary positioning can meaningfully change what your plan actually spends, regardless of what your coverage policy says on paper.

The employers who are getting GLP-1 right in 2026 are not the ones with the most generous policies or the most restrictive ones. They are the ones with the most deliberately structured policies. That deliberateness starts before renewal — not during it.

Ready to build a GLP-1 coverage strategy that protects your plan without alienating your workforce? The team at Tooher-Ferraris has been helping businesses navigate complex benefits decisions since 1932. Contact us today to schedule a no-obligation consultation.